Innovation Pharmaceuticals Inc.
IPIX
$0.0002
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.56% | -51.89% | -39.66% | -13.06% | 18.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.97% | -54.49% | -56.04% | -83.47% | -31.69% |
| Operating Income | 41.97% | 53.84% | 56.04% | 83.47% | 31.69% |
| Income Before Tax | 38.38% | 58.12% | 53.03% | 80.73% | 30.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.38% | 58.12% | 53.03% | 80.73% | 30.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.38% | 58.12% | 53.03% | 80.73% | 30.54% |
| EBIT | 41.97% | 53.84% | 56.04% | 83.47% | 31.69% |
| EBITDA | 45.07% | 58.01% | 59.79% | 87.54% | 33.14% |
| EPS Basic | 39.29% | 48.00% | 56.25% | 82.93% | 37.78% |
| Normalized Basic EPS | 38.89% | 42.86% | 55.00% | 85.71% | 35.71% |
| EPS Diluted | 39.29% | 48.00% | 56.25% | 82.93% | 37.78% |
| Normalized Diluted EPS | 38.89% | 42.86% | 55.00% | 85.71% | 35.71% |
| Average Basic Shares Outstanding | 2.85% | -19.50% | 6.17% | 10.25% | 11.31% |
| Average Diluted Shares Outstanding | 2.85% | -19.50% | 6.17% | 10.25% | 11.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |